My Member
Message Center
trending topics
market reports
-
Visit MEDICAL JAPAN 2023 TOKYO and take full advantage of the business opportunities!
2023-09-01
-
US to distribute 400 million free N95 masks at CVS, Walgreens in COVID fight
2022-01-21
-
Ethiopia receives additional 2.2 mln doses of Chinese-donated COVID-19 vaccines
2022-01-21
-
Hong Kong researchers say they develop novel material able to kill COVID-19 virus
2022-01-14
-
10 million more Chinese doses on way for Kenya
2022-01-14
-
Sino-African ties on track for a brighter future
2022-01-07
-
Efforts urged to boost COVID-19 vaccine production capacity in poor countries
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
Zimbabwe buoyed by Chinese jabs
2021-12-31
Another Chinese adenovirus vector COVID-19 vaccine ready for human trials
2020-12-30
[Photo/VCG]
BEIJING -- One more Chinese adenovirus vector vaccine candidate against COVID-19 is ready for human trials at home and abroad, its developers said Monday.
Researchers from Tsinghua University, Tianjin Medical University and Kunming-based Walvax Biotechnology Co., Ltd. have started developing the vaccine since the outbreak of the epidemic. Compared with other candidates, it was produced using chimpanzee blood.
Because there is generally no pre-stored neutralizing antibody against chimpanzee adenovirus in the human body, the vaccine with this virus as the carrier will have the advantages of low adverse reactions, high production capacity and strong immunity after vaccination, said lead researcher Zhang Linqi, from Tsinghua University.
The vaccine makers have completed animal tests and started applying to launch human trials in China and overseas.
"No serious side effects have occurred in animals," said Zhang, adding that the results of the preclinical research support the safety of this vaccine and suggest the potential for further clinical tests.
Zhang noted that phase-3 clinical trials to verify the vaccine efficacy will be performed in pandemic areas abroad. "Like other Chinese COVID-19 vaccines, we are also facing the situation that there are not enough COVID-19 patients in China to participate in phase-3 trials."
An industrialization base of the patented chimpanzee adenovirus vector vaccine was launched Sunday in Beijing's Daxing District. Once the vaccine is proved effective after trials, it will be mass produced in the base.
The manufacturing plants are now under construction, and the vaccine is likely to hit market in mid-2021. The annual production capacity for the COVID-19 vaccine will top 200 million doses, according to a Walvax statement.
China currently has five vaccines entering phase-3 clinical trials including an adenovirus vector vaccine developed by the Academy of Military Sciences and CanSino Biologics Inc., said an official from the National Health Commission earlier in December.
（China Daily）
